{"filing":{"accession_number":"0001213900-26-093015","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-08-24","report_date":"2026-08-24","primary_document":"ea0303144-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026093015/ea0303144-6k_clearmind.htm"},"events":[{"id":29135,"run_id":26661,"accession_number":"0001213900-26-093015","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces the U.S. publication of a patent application covering a novel MDMA-N-acylethanolamines combination for treating PTSD, anxiety, and eating disorders, resulting from Clearmind's collaboration with NeuroThera Labs. The disclosure highlights intellectual property advancement (13 patent applications generated through the collaboration, now 19 patent families total) and notes the FDA's recent finalization of guidance explicitly including MDMA in its psychedelic drug development framework. While this is a material operational and strategic milestone for a clinical-stage biotech—expanding IP portfolio and regulatory clarity—it does not fit the discrete event categories of earnings release, M\u0026A activity, executive changes, or other specific material events. The patent publication and regulatory context represent a significant operational/strategic development that would affect investor assessment of the company's pipeline and competitive position.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-08-24","form":"6-K","submitted_at":null,"items":[{"id":31308,"accession_number":"0001213900-26-093015","item_number":"EX-99.1","item_title":"ea030314402ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces the U.S. publication of a patent application covering a novel MDMA-N-acylethanolamines combination for treating PTSD, anxiety, and eating disorders, resulting from Clearmind's collaboration with NeuroThera Labs. The disclosure highlights intellectual property advancement (13 patent applications generated through the collaboration, now 19 patent families total) and notes the FDA's recent finalization of guidance explicitly including MDMA in its psychedelic drug development framework. While this is a material operational and strategic milestone for a clinical-stage biotech—expanding IP portfolio and regulatory clarity—it does not fit the discrete event categories of earnings release, M\u0026A activity, executive changes, or other specific material events. The patent publication and regulatory context represent a significant operational/strategic development that would affect investor assessment of the company's pipeline and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-24T20:01:54.877224+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31308,"accession_number":"0001213900-26-093015","item_number":"EX-99.1","item_title":"ea030314402ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces the U.S. publication of a patent application covering a novel MDMA-N-acylethanolamines combination for treating PTSD, anxiety, and eating disorders, resulting from Clearmind's collaboration with NeuroThera Labs. The disclosure highlights intellectual property advancement (13 patent applications generated through the collaboration, now 19 patent families total) and notes the FDA's recent finalization of guidance explicitly including MDMA in its psychedelic drug development framework. While this is a material operational and strategic milestone for a clinical-stage biotech—expanding IP portfolio and regulatory clarity—it does not fit the discrete event categories of earnings release, M\u0026A activity, executive changes, or other specific material events. The patent publication and regulatory context represent a significant operational/strategic development that would affect investor assessment of the company's pipeline and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-24T20:01:54.877224+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-08-24"}]}